BeOne Medicines Ltd. ONC
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. 10-K, Item 1
- Employees
- 12,000
- Headquarters
- Basel
- CEO
- John Oyler
- Next results
- around Feb 25, 2027
Where each dollar of revenue went, FY2025
Revenue of $5.3B through the costs to a net profit of $286.9M · income statement of the 10-K
ONC among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
32 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Gross-to-Net U.S. Accruals for Sales Chargebacks and Third-Party Managed Rebates (“At December 31, 2025, the Company recorded $79.1 million of contra AR accruals and $398.5 million of accrued rebates, returns and other deductions. As discussed in Note 2 to the consolidated financial statements under the caption “Revenue Recognition,” the Company recognizes revenue when the transfe”). No longer listed: Product Revenue, Net
-
Receivables +27.9% ($676.3M to $865.1M) vs revenue +40.2% ($3.8B to $5.3B), -12.3 pts apart
9 more checks with nothing to note
-
Cash from operations $1.1B vs net income $286.9M (FY ending Dec 31, 2025)
-
Inventory +22.9% ($495.0M to $608.2M) vs revenue +40.2% ($3.8B to $5.3B), -17.4 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
32 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In April 2025, the Trump administration published Executive Order 14273 (90 Fed. Reg. 16441), “Lowering Drug Prices by Once Again Putting Americans First,” which generally directs the U.S. Department of Health and Human Services (“HHS”) to take steps to reduce drug prices. In May 2025, the administration published Executive Order 14297…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Furthermore, on April 1, 2025, the Bureau of Industry and Security of the U.S. Department of Commerce (“BIS”) initiated an investigation into whether imports of pharmaceutical products present a risk to the national security of the U.S. This investigation could result in BIS recommending additional tariffs on imports of pharmaceutical…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and we cannot predict with any certainty the success of any clinical trial or whether or when we might complete a given clinical trial. We may also experience…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business. On May 12, 2025, President Trump issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S.…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.4B | $2.5B | $3.8B | $5.3B |
| Net income | −$2.0B | −$881.7M | −$644.8M | $286.9M |
| Operating cash flow | −$1.5B | −$1.2B | −$140.6M | $1.1B |
| Free cash flow | −$1.8B | −$1.7B | −$633.3M | $941.7M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$5.3B ▲ 40.2% in FY2025$286.9M in FY2025$941.7M in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 6, 2026TITUS BENJAMIN BALL (Officer) gave notice of a planned sale of 1,559 shares worth about $632K Form 144, approximate sale date Nov 6, 2026
-
Planned saleNov 5, 2026CHAN LEE (Officer) gave notice of a planned sale of 1,115 shares worth about $421K Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted May 29, 2026
-
Planned saleNov 5, 2026Xiaobin Wu (President and Chief Operating Officer) ended a 10b5-1 trading plan reported in the 10-Q, up to 86,082 shares, runs to Dec 15, 2027
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
BeOne Medicines Ltd., Basel · from the 10-K filed Feb 26, 2026
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
- Headquarters
- Basel
- Reports in
- USD
- Listed on
- Nasdaq, OTC
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
Employees, at the top of the page: "As of February 13, 2026, we had nearly 12,000 full-time employees worldwide, across six continents, with approximately 1,900 employees in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.